Intellia Therapeutics Names Brian Goff to its Board of Directors
CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on...
Month: June 2024
Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association (EHA) 2024 Congress
WATERTOWN, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery,...
Brixton Metals Appoints Patrick Highsmith to its Board of Directors
VANCOUVER, British Columbia, June 14, 2024 (GLOBE NEWSWIRE) -- Brixton Metals Corporation (TSX-V: BBB, OTCQB: BBBXF) (the “Company” or “Brixton”)...
Plato Gold Welcomes Mr. Ernie J. Marcotte to the Board of Directors
Toronto, ON, June 14, 2024 (GLOBE NEWSWIRE) -- Plato Gold Corp. (TSX-V: PGC) (OTCQB: NIOVF) (Frankfurt: 4Y7 or WKN: A0M2QX)...
Bio-Path Holdings Presents Data from Ongoing Phase 2 Combination Study of Prexigebersen for Treatment of Acute Myeloid Leukemia at European Hematology Association Congress
HOUSTON, June 14, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery...
Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
LONDON, June 14, 2024 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell...
VERSABANK RECEIVES FINAL U.S. APPROVAL FOR U.S. BANK ACQUISITON
– Acquisition Will Enable VersaBank to Broadly Launch its Unique and Highly Successful Receivable Purchase Program Financing Solution in the United...
Tilray Beverages Announces Campaign to Raise Awareness for Men’s Health
NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray Brands” or “Tilray”) (Nasdaq | TSX: TLRY), a...
TScan Therapeutics Announces Updates to its Board of Directors
Garry A. Nicholson, an experienced executive with regulatory and commercial expertise, joins the Board of DirectorsTimothy Barberich retires as Chair;...
Syndax Presents Updated Positive Data from BEAT AML and AUGMENT-102 Phase 1/2 Combination Trials of Revumenib in Patients with Acute Leukemias at EHA 2024 Congress
- Data continue to support revumenib's potential to enhance current standard of care agents - - 96% CRc (23 of...
Medicare Issues Final Coverage Determination for kidneyintelX.dkd
LONDON and NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that on June 13, 2024 Medicare...
Chicago Atlantic Real Estate Finance Declares Common Stock Dividend of $0.47 for the Second Quarter of 2024
CHICAGO, June 14, 2024 (GLOBE NEWSWIRE) -- Chicago Atlantic Real Estate Finance, Inc. (NASDAQ: REFI), a commercial mortgage real estate...
Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
KT-333 demonstrated initial clinical proof of concept across multiple hematological malignancies, including complete responses in two patients with Hodgkin’s lymphomaRead...
Invivyd Announces Antiviral Activity of VYD222 (pemivibart) Against SARS-CoV-2 KP.1.1 FLiRT & KP.3 Variants
WALTHAM, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from...
Ragnarok Online Official Launching in China on June 28, 2024
Seoul, South Korea, June 14, 2024 (GLOBE NEWSWIRE) -- GRAVITY Co., Ltd. (NasdaqGM: GRVY) (“Gravity” or “Company”), a developer and...
Generation Bio to Present at the 2024 TD Cowen Genetic Medicines & RNA Summit
CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people...
First Interstate BancSystem, Inc. Announces President and CEO Kevin P. Riley’s Retirement
Contacts Company Contact: David Della Camera, CFA Deputy Chief Financial Officer (406) 255-5363 investor.relations@fib.com Media Contact: Sara Becker Director of...
enGene Reports Second Quarter 2024 Financial Results and Provides a Business Update
Company announces plans for initial indication expansion for EG-70 into high-risk papillary-only NMIBC Contacts For media contact: media@engene.com For investor...
CNB Community Bancorp, Inc. Declares Quarterly Cash Dividend of $0.29 Per Share
HILLSDALE, Mich., June 14, 2024 /PRNewswire/ -- CNB Community Bancorp, Inc. (OTCQX:CNBB) announced that the Board of Directors has declared...
Flagship Communities Real Estate Investment Trust Announces June 2024 Cash Distribution
Not for distribution to U.S. newswire services or dissemination in the United States.TORONTO, June 14, 2024 (GLOBE NEWSWIRE) -- Flagship...
Virginia529 Selects eGain AI Knowledge to Elevate Customer and Advisor Experience
SUNNYVALE, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- eGain (NASDAQ: EGAN), the leading AI knowledge platform for customer service, today...
CORRECTION BY SOURCE: Crown Equity Holdings Inc. Announces New Chairman of the Board
DUE TO MULTIPLE REVISIONS, THE FOLLOWING CORRECTS AND REPLACES THE RELEASE THAT WAS ISSUED EARLIER TODAY LAS VEGAS, NV /...
Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024
Tibulizumab (ZB-106) was well tolerated and neutralized IL-17A and BAFF in a Phase 1 study in patients with Sjogren’s syndrome...
Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid
– Observed 67% Objective Response Rate (ORR) in frontline HR-MDS patients, primarily with TP53 mutations; initial complete remission (CR)/marrow complete...
Greenwich LifeSciences Announces $2.5 Million Private Placement
STAFFORD, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company" or "Greenwich"), a clinical-stage biopharmaceutical...
The Ensign Group, Inc. Declares Quarterly Dividend of $0.06 Per Share
SAN JUAN CAPISTRANO, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group...
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024
Arm D of SEQUOIA study evaluated treatment-naïve patients with high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma with del(17p) and/or...
Chilean Cobalt Corp. Announces Receipt of USD $317 Million Letter of Interest From US EXIM Bank
BERWYN, PA / ACCESSWIRE / June 14, 2024 / Chilean Cobalt Corp. (OTCQB:COBA) ("C3" or the "Company") is pleased to...
CMC Metals Oversubscribes Private Placement
VANCOUVER, BC / ACCESSWIRE / June 14, 2024 / CMC Metals Ltd. (TSXV:CMB)(FRA:ZM5P)(OTCQB:CMCXF) ("CMC" or the "Company") has oversubscribed its...
Crown Equity Holdings, Inc. Announces New Chairman of Board
LAS VEGAS, NV / ACCESSWIRE / June 14, 2024 / Crown Equity Holdings, Inc. (OTC PINK:CRWE) today announced the appointment...
SMC Announces Retirement of $442,875 of Debt
BOCA RATON, FL / ACCESSWIRE / June 14, 2024 / SMC Entertainment, Inc. ("SMC" or the "Company") (OTC PINK:SMCE), a...
Protagonist Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showing Durable Hematocrit Control
Long term follow-up from REVIVE Phase 2 study up to 3 years shows durable hematocrit (Hct) control (< 45%), decreased...
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
All patients treated in the RUBY trial are free of vaso-occlusive events post-renizgamglogene autogedtemcel (reni-cel) infusionPatients had early normalization of...
Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease
MADRID, June 14, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through...
Vertex Presents Positive Long-Term Data On CASGEVY™ (exagamglogene autotemcel) at the 2024 Annual European Hematology Association (EHA) Congress
- Results from CLIMB-111, -121 and -131 accepted for oral presentation - - Data from these trials, with the longest...
Rigel Announces Five Presentations at the EHA2024 Hybrid Congress
- Oral presentation highlighting final five-year efficacy data from the registrational Phase 2 trial of REZLIDHIA® (olutasidenib) in heavily...
New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment
– Analysis Shows Manufacturing of Yescarta in Second-Line Treatment of Relapsed/Refractory Large B-cell Lymphoma Can Help Reduce Time from Leukapheresis...
Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
All patients treated in the EdiTHAL trial maintained hemoglobin levels above the transfusion threshold and are transfusion-free post-renizgamglogene autogedtemcel (reni-cel)...
Irving Resources Reports Non-Brokered Private Placement
NOT FOR DISSEMINATION IN THE UNITED STATES OR DISTRIBUTION TO U.S. WIRE SERVICES VANCOUVER, BC / ACCESSWIRE / June 14,...
Vertex erwirbt Steuerfähigkeiten im Bereich der künstlichen Intelligenz von Ryan, LLC
KING OF PRUSSIA, Pennsylvania, June 14, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX) („Vertex“ oder das „Unternehmen“), ein globaler Anbieter von...